Equity Overview
Price & Market Data
Price: $2.20
Daily Change: -$0.0186 / 0.84%
Daily Range: $2.17 - $2.28
Market Cap: $664,844,007
Daily Volume: 816,186
Performance Metrics
1 Week: -14.01%
1 Month: -23.26%
3 Months: -26.33%
6 Months: 151.7%
1 Year: 7.80%
YTD: 27.75%
Company Details
Employees: 204
Sector: Health technology
Industry: Biotechnology
Country:
Details
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.